美國新型冠狀病毒 (COVID-19) 疫苗和治療藥物的後續行動 - 市場洞察和趨勢（2021 年上半年）
US COVID-19 Vaccines and Therapeutics Tracker-Market Insights and Trends, H1 2021
|出版商||Frost & Sullivan||商品編碼||1006498|
|出版日期||內容資訊||英文 53 Pages
|美國新型冠狀病毒 (COVID-19) 疫苗和治療藥物的後續行動 - 市場洞察和趨勢（2021 年上半年） US COVID-19 Vaccines and Therapeutics Tracker-Market Insights and Trends, H1 2021|
|出版日期: 2021年04月30日||內容資訊: 英文 53 Pages||
截至 2021 年 3 月 31 日，美國食品藥品監督管理局 (FDA) 已授予Pfizer□BioNTech、Moderna、Johnson & Johnson 生產的三種疫苗的緊急使用授權。 Novavax 和AstraZeneca生產的候選疫苗預計將於 2021 年第二季度獲得批准。
Agnostic Vaccine Platform Technology Enhancing Future Growth Potential of Participants in the Value Chain
This study by Frost & Sullivan's Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants. The US response to the pandemic has been disorganized and made worse with the politicization of vaccine approval and distribution, creating distrust and delaying the country's vaccination program. Each state in the US has its own vaccination strategy and as such, state health department websites are critical sources of information on when, where, and how to get vaccines.
As of 31 March 2021, the US Food & Drug Administration granted Emergency Use Authorization to three vaccines manufactured respectively by Pfizer and BioNTech, Moderna, and Johnson & Johnson. Novavax and AstraZeneca vaccines are two other leading vaccine candidates expected to be approved for use in Q2 2021. Apart from vaccines, drugs are likely to play a critical role in treating individuals not responding to vaccines, not receiving vaccines, and who still contracted the virus despite vaccination.
Maintaining vaccine integrity through all stages of the supply chain requires never-before-seen levels of monitoring and coordination among stakeholders. Partnerships between input supply firms and distributors are as critical as collaborations between vaccine sponsors and contract manufacturers to scale up production for mass immunization.
Key topics covered in the study include: